FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2046346032> ?p ?o ?g. }

• W2046346032 endingPage "908" @default.
• W2046346032 startingPage "896" @default.
• W2046346032 abstract "Control of metastatic prostate cancer (CaP) is an elusive objective. Some 30% of patients with clinically localized CaP will develop micrometastatic disease. Defining the expression of tumor-associated antigens on CaP will enable appropriate selection of therapeutic targets.The expression of tumor-associated antigens on CaP cell lines (PC-3, DU 145, and LNCaP-LN3) was detected by immunohistochemistry and flow cytometry. Test and control alpha-conjugates were prepared using monoclonal antibodies, an inhibitor, plasminogen activator inhibitor type 2, that binds to the cell-membrane-bound protease, urokinase plasminogen activator, and a control protein labeled with (213)Bi using standard methods. These were used singly or together against three different CaP cell lines in vitro. The cytotoxicity of the alpha-conjugates was assessed using the [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] (MTS) assay.The PC-3 and DU 145 cancer cell lines expressed antigens that bind monoclonal antibodies BLCA-38 and #394 (mouse anti-human urokinase plasminogen activator B-chain) but not J591. The LNCaP-LN3 cells bound J591 but not #394 or BLCA-38. For the PC-3, DU 145, and LNCaP-LN3 cell lines, multiple-targeted alpha-therapy combining four alpha-conjugates (one-quarter doses of each) gave D(0) (37% cell survival) values of 15, 17, and 27 microCi/mL compared with those of the controls of 272, 289, and 281 microCi/mL, respectively.Metastatic prostate cancer-associated antigens recognized by multiple monoclonal antibodies are potential targets for alpha-therapy. Multiple-targeted alpha-therapy produced cytotoxicity specific to three CaP cell lines and may form the basis of treatment for micrometastatic CaP, overcoming the heterogeneity of expression of the targeted antigens." @default.
• W2046346032 created "2016-06-24" @default.
• W2046346032 creator A5015436826 @default.
• W2046346032 creator A5026205310 @default.
• W2046346032 creator A5044115470 @default.
• W2046346032 creator A5044857725 @default.
• W2046346032 creator A5049944596 @default.
• W2046346032 creator A5059586100 @default.
• W2046346032 creator A5069036179 @default.
• W2046346032 creator A5073920233 @default.
• W2046346032 creator A5084722353 @default.
• W2046346032 creator A5086810315 @default.
• W2046346032 date "2004-11-01" @default.
• W2046346032 modified "2023-09-28" @default.
• W2046346032 title "Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted α-therapy with 213Bi-conjugates" @default.
• W2046346032 cites W100467445 @default.
• W2046346032 cites W1541668845 @default.
• W2046346032 cites W1963575875 @default.
• W2046346032 cites W1963586151 @default.
• W2046346032 cites W1967366986 @default.
• W2046346032 cites W1974964441 @default.
• W2046346032 cites W1977659044 @default.
• W2046346032 cites W1982680133 @default.
• W2046346032 cites W1986170691 @default.
• W2046346032 cites W1987223060 @default.
• W2046346032 cites W1992119878 @default.
• W2046346032 cites W1997375815 @default.
• W2046346032 cites W2000008804 @default.
• W2046346032 cites W2009012461 @default.
• W2046346032 cites W2014145760 @default.
• W2046346032 cites W2015715679 @default.
• W2046346032 cites W2016973566 @default.
• W2046346032 cites W2017101953 @default.
• W2046346032 cites W2027337391 @default.
• W2046346032 cites W2033576653 @default.
• W2046346032 cites W2046386902 @default.
• W2046346032 cites W2057330068 @default.
• W2046346032 cites W2072475957 @default.
• W2046346032 cites W2074544671 @default.
• W2046346032 cites W2077109111 @default.
• W2046346032 cites W2088283955 @default.
• W2046346032 cites W2110071962 @default.
• W2046346032 cites W2123927174 @default.
• W2046346032 cites W2138302361 @default.
• W2046346032 cites W2143689328 @default.
• W2046346032 cites W2156115176 @default.
• W2046346032 cites W2278969192 @default.
• W2046346032 cites W2316331910 @default.
• W2046346032 cites W2398661098 @default.
• W2046346032 cites W2415686293 @default.
• W2046346032 cites W2417303506 @default.
• W2046346032 cites W2440014071 @default.
• W2046346032 cites W2468722314 @default.
• W2046346032 cites W2577055267 @default.
• W2046346032 cites W38263071 @default.
• W2046346032 cites W4231272674 @default.
• W2046346032 cites W4250808099 @default.
• W2046346032 cites W4255816703 @default.
• W2046346032 doi "https://doi.org/10.1016/j.ijrobp.2004.04.035" @default.
• W2046346032 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15465208" @default.
• W2046346032 hasPublicationYear "2004" @default.
• W2046346032 type Work @default.
• W2046346032 sameAs 2046346032 @default.
• W2046346032 citedByCount "18" @default.
• W2046346032 countsByYear W20463460322012 @default.
• W2046346032 countsByYear W20463460322013 @default.
• W2046346032 countsByYear W20463460322014 @default.
• W2046346032 countsByYear W20463460322015 @default.
• W2046346032 countsByYear W20463460322019 @default.
• W2046346032 crossrefType "journal-article" @default.
• W2046346032 hasAuthorship W2046346032A5015436826 @default.
• W2046346032 hasAuthorship W2046346032A5026205310 @default.
• W2046346032 hasAuthorship W2046346032A5044115470 @default.
• W2046346032 hasAuthorship W2046346032A5044857725 @default.
• W2046346032 hasAuthorship W2046346032A5049944596 @default.
• W2046346032 hasAuthorship W2046346032A5059586100 @default.
• W2046346032 hasAuthorship W2046346032A5069036179 @default.
• W2046346032 hasAuthorship W2046346032A5073920233 @default.
• W2046346032 hasAuthorship W2046346032A5084722353 @default.
• W2046346032 hasAuthorship W2046346032A5086810315 @default.
• W2046346032 hasConcept C109316439 @default.
• W2046346032 hasConcept C121608353 @default.
• W2046346032 hasConcept C126322002 @default.
• W2046346032 hasConcept C147483822 @default.
• W2046346032 hasConcept C153911025 @default.
• W2046346032 hasConcept C159654299 @default.
• W2046346032 hasConcept C202751555 @default.
• W2046346032 hasConcept C203014093 @default.
• W2046346032 hasConcept C2779679481 @default.
• W2046346032 hasConcept C2779723316 @default.
• W2046346032 hasConcept C2780192828 @default.
• W2046346032 hasConcept C502942594 @default.
• W2046346032 hasConcept C542903549 @default.
• W2046346032 hasConcept C54355233 @default.
• W2046346032 hasConcept C553184892 @default.
• W2046346032 hasConcept C55493867 @default.
• W2046346032 hasConcept C71924100 @default.
• W2046346032 hasConcept C81885089 @default.

• next